The Swiss drugmaker said Tuesday it would initiate a Phase III trial of 450 patients to test Ilaris as a treatment for cytokine release syndrome in Covid-19 pneumonia patients.

LEAVE A REPLY

Please enter your comment!
Please enter your name here